Gilead
See the following -
A Law Professor’s Big Idea for Combating Greedy Drug Company Titans Like Martin Shkreli
In 2015, CEO of Turing Pharmaceuticals Martin Shkreli infamously raised the price of the life-saving drug Daraprim by 5,000%. Daraprim, developed more than 60 years ago, is used to treat the deadly parasitic infection toxoplasmosis. It was selling for $13.50 a pill; then Turing raised the price to $750. The move sparked massive backlash and Congressional hearings, and Shkreli himself was eventually arrested for, and convicted of, unrelated securities fraud charges. But the original, horrible problem didn’t get fixed. Turing kept the price sky-high; as of August 2016, many patients were paying $375 per pill...
- Login to post comments
Ahead Of Obama Visit, MSF Warns US Pressure On India Could Impact Access To Medicines For Millions
Ahead of US President Obama’s visit to India, the international medical humanitarian organisation Medecins Sans Frontieres/ Doctors Without Borders (MSF) expressed deep concern over the US government’s heightened efforts to undermine access to affordable medicines from India—often called the ‘pharmacy of the developing world.’...
- Login to post comments
Let's Pay For Open Source With A Closed-Source Software Levy
This column has often explored ways in which some of the key ideas underlying free software and open source are being applied in other fields. But that equivalence can flow in both directions: developments in fields outside the digital world may well have useful lessons for computing...
- Login to post comments
Mylan Isn't Alone: 11 Drugmakers with Off-the-Charts Pricing Power
Mylan (MYL) is drawing fire for passing off massive price hikes for its EpiPen allergy treatment. But it’s far from being the drug company with the most pricing power. Gilead (GILD), Biogen (BIIB) and Amgen (AMGN), along with eight other drug giants in the Standard & Poor's 500, enjoyed off-the-charts pricing power on their products relative to costs — far beyond Mylan's, according to a USA TODAY analysis of data from S&P Global Market Intelligence...
- Login to post comments